Heteroaryl, heterocyclic and aryl compounds which inhibit...

Details Heteroaryl, heterocyclic and aryl compounds which inhibit... Heteroaryl, heterocyclic and aryl compounds which inhibit...

2006-10-16

2010-06-22

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S224000, C544S242000

Reexamination Certificate

active

07741328

ABSTRACT:
Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

REFERENCES:
patent: 4018913 (1977-04-01), Okamoto et al.
patent: 4018915 (1977-04-01), Okamoto et al.
patent: 4036955 (1977-07-01), Okamoto et al.
patent: 4041156 (1977-08-01), Okamoto et al.
patent: 4046876 (1977-09-01), Okamoto et al.
patent: 4055636 (1977-10-01), Okamoto et al.
patent: 4055651 (1977-10-01), Okamoto et al.
patent: 4070457 (1978-01-01), Okamoto et al.
patent: 4073914 (1978-02-01), Kikumoto et al.
patent: 4085057 (1978-04-01), Masuda et al.
patent: 4096255 (1978-06-01), Kikumoto et al.
patent: 4104392 (1978-08-01), Okamoto et al.
patent: 4235871 (1980-11-01), Papahadjopoulos et al.
patent: 4438122 (1984-03-01), Holmwood et al.
patent: 4501728 (1985-02-01), Geho et al.
patent: 4505910 (1985-03-01), Bagli
patent: 4518600 (1985-05-01), Holmwood et al.
patent: 4544402 (1985-10-01), Schnurbusch et al.
patent: 4559345 (1985-12-01), Gomarasca et al.
patent: 4672065 (1987-06-01), Spatz
patent: 4837028 (1989-06-01), Allen
patent: 4908368 (1990-03-01), Murase et al.
patent: 4959364 (1990-09-01), Mueller et al.
patent: 4992439 (1991-02-01), Meanwell
patent: 5011472 (1991-04-01), Aebischer et al.
patent: 5023252 (1991-06-01), Hseih et al.
patent: 5030644 (1991-07-01), Baldwin et al.
patent: 5120734 (1992-06-01), Klausener et al.
patent: 5238934 (1993-08-01), Knuppel et al.
patent: 5278184 (1994-01-01), Artico et al.
patent: 5510332 (1996-04-01), Kogan et al.
patent: 5580868 (1996-12-01), Lunkenheimer et al.
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 5814643 (1998-09-01), Duggan et al.
patent: 5861429 (1999-01-01), Sato et al.
patent: 5925644 (1999-07-01), Jakobi et al.
patent: 5942504 (1999-08-01), Grobelny
patent: 5955491 (1999-09-01), Sohda et al.
patent: 5962479 (1999-10-01), Chen
patent: 5972946 (1999-10-01), Murata et al.
patent: 6005117 (1999-12-01), Wehner et al.
patent: 6436904 (2002-08-01), Ashwell et al.
patent: 6479492 (2002-11-01), Konradi et al.
patent: 6492372 (2002-12-01), Konradi et al.
patent: 6544994 (2003-04-01), Rabelink et al.
patent: 6545003 (2003-04-01), Grant et al.
patent: 6689781 (2004-02-01), Konradi et al.
patent: 6794506 (2004-09-01), Konradi et al.
patent: 6903088 (2005-06-01), Konradi et al.
patent: 6911439 (2005-06-01), Konradi et al.
patent: 7005433 (2006-02-01), Konradi et al.
patent: 7008949 (2006-03-01), Konradi et al.
patent: 7026328 (2006-04-01), Konradi et al.
patent: 7049306 (2006-05-01), Konradi et al.
patent: 7135477 (2006-11-01), Konradi et al.
patent: 7335663 (2008-02-01), Konradi et al.
patent: 7378529 (2008-05-01), Konradi et al.
patent: 7427628 (2008-09-01), Konradi et al.
patent: 7452912 (2008-11-01), Grant et al.
patent: 2005/0203093 (2005-09-01), Konradi et al.
patent: 2005/0261293 (2005-11-01), Konradi et al.
patent: 2006/0013799 (2006-01-01), Konradi et al.
patent: 2007/0099921 (2007-05-01), Konradi et al.
patent: 2007/0129390 (2007-06-01), Semko et al.
patent: 2007/0142416 (2007-06-01), Semko et al.
patent: 2008/0058357 (2008-03-01), Smith et al.
patent: 2241149 (1997-07-01), None
patent: 2259224 (1998-01-01), None
patent: 2359115 (2000-07-01), None
patent: 19536891 (1997-04-01), None
patent: 2655636 (1997-06-01), None
patent: 19548709 (1997-07-01), None
patent: 19654483 (1998-01-01), None
patent: 19713000 (1998-10-01), None
patent: 116494 (1984-08-01), None
patent: 0 147 211 (1985-07-01), None
patent: 0 288 176 (1988-10-01), None
patent: 0330506 (1989-08-01), None
patent: 0330506 (1989-08-01), None
patent: 0 526 348 (1993-02-01), None
patent: 0 535 512 (1993-04-01), None
patent: 0 535 521 (1993-04-01), None
patent: 1500063 (1978-02-01), None
patent: 169926 (1977-02-01), None
patent: 59212480 (1984-12-01), None
patent: WO 91/05038 (1991-04-01), None
patent: WO 92/16549 (1992-10-01), None
patent: WO 93/12809 (1993-07-01), None
patent: WO 93/24154 (1993-12-01), None
patent: WO 96/01644 (1996-01-01), None
patent: WO 96/22966 (1996-08-01), None
patent: WO 96/32383 (1997-04-01), None
patent: WO 97/23451 (1997-07-01), None
patent: WO 97/48726 (1997-12-01), None
patent: WO 98/00395 (1998-01-01), None
patent: WO 98/22430 (1998-05-01), None
patent: WO 98/33783 (1998-08-01), None
patent: WO 98/53814 (1998-12-01), None
patent: WO 98/53817 (1998-12-01), None
patent: WO 99/06390 (1999-02-01), None
patent: WO 99/06391 (1999-02-01), None
patent: WO 99/06431 (1999-02-01), None
patent: WO 99/06432 (1999-02-01), None
patent: WO 99/06433 (1999-02-01), None
patent: WO 00/10313 (1999-03-01), None
patent: WO 99/10312 (1999-03-01), None
patent: WO 99/37605 (1999-07-01), None
patent: WO 99/37618 (1999-07-01), None
patent: WO 99/52898 (1999-10-01), None
patent: WO 00/18759 (2000-04-01), None
patent: WO 00/31067 (2000-06-01), None
patent: WO 00/43369 (2000-07-01), None
patent: WO 00/43371 (2000-07-01), None
patent: WO 00/43372 (2000-07-01), None
patent: WO 02/08201 (2002-01-01), None
patent: WO 03/099231 (2003-12-01), None
patent: WO 03/099809 (2003-12-01), None
patent: WO 2005/111020 (2005-11-01), None
patent: WO 2007/041270 (2007-04-01), None
patent: WO 2007/041324 (2007-04-01), None
patent: WO 2007/101165 (2007-09-01), None
Hladon, Buguslaw et al., In Vitro cytostatic activity of some amino acid 4-N-substituted cytosines,Arch. Immunol. Ther. Exp. (1992), 40(2), 145-50. (Abstract).
Hoffman, Seigfried; Schubert, Herman; Nitsche, Klaus, N-Pyrimidinylamino acids. III. N-(oxopyrimidinyl) derivatives of neutral amino acids,Z. Chem. (1972), 12(1) 21-2, CODEN: ZECEAL (Abstract).
Teranishi, Katsunori; Goto, Toshio, Synthesis and Chemiluminescense of Coelenterazine (Oplophorus Luciferin) analogs,Bull. Chem. Soc. Jpn. (1990), 63(11), 3132-40 , (Abstract).
Abraham, W.M., et al. “α4-Integrins Mediate Antigen -induced Late Bronchial Responses and Prolonged Airway Hyperresponsiveness in Sheep.”J. Clin. Invest. 93: 776-787 (1994).
Bao, L., et al. “Correlation of VLA-4 integrin expression with metastatic potential in various human tumour cell lines.”Diff. 52: 239-246 (1993).
Baron, J.L., et al. “Surface Expression of α4 Integrin by CD4 T Cells is Required for Their Entry into Brain Parenchyma.”J. Exp. Med. 177: 57-68 (1993).
Baron, J.L., et al. et al. “The Pathogenesis of Adeoptive Murine Autonimmune Diabetes Requires an Interaction between α4-Integrins and Vascular Cell Adhesion Molecule-1.”J. Clin. Invest. 93: 1700-1708 (1994).
Burkly, L.C., et al. “Protection Against Adoptive Transfer of Autoimmune Diabetes Mediated Through Very Late Antigent-4 Integrin.”Diabetes. 43: 529-534 (1994).
Cybulsky, M.I., et al. “Endothelial Expression of a Mononuclear Leukocyte Adhesion Molecule During Atherogenesis.”Science. 251: 788-791 (1991).
Elices, M.J., et al. “Expression and Functional Significance of Alternatively Spliced CS1 Fibronecting in Rheumatoid Arthritis Microvasculature.”J. Clin. Invest. 93: 405-416 (1994).
Elices, M.J., et al. “VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distinct from the CLA-4/Fibronectin Binding Site.”Cell. 60: 577-584 (1990).
Hamann, A., et al. “Role of α4-Integrins in Lymphocute Homing to Mucosal Tissues in Vivo.”J. Immunology. 152: 3283-3292 (1994).
Hladon, B., et al. In Vitro cytostatic activity of some amino acid 4-N-substituted cytosines.Arch. Immunol. Ther. Exp. 40(2): 145-150 (1992). (Abstract).
Hoffman, S., et al. “N-Pyrimidinylamino acids. III. N-(oxopyrimidinyl) derivatives of neutral amino acids.”Z. Chem. 12(1): 21-22 (1972), CODEN: ZECEAL (Abstract)

Affiliated with

Also associated with

Rating

Heteroaryl, heterocyclic and aryl compounds which inhibit... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heteroaryl, heterocyclic and aryl compounds which inhibit..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl, heterocyclic and aryl compounds which inhibit... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4195497